H. Lundbeck A/S (Lundbeck) today announced the acceptance of its new drug application (NDA) for Vyepti® (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback